Second-Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer
Open Access
Abstract
Ras homologous A (RHOA), a signal mediator and a GTPase, is known to be associated with the progression of gastric cancer (GC), which is the fourth most common cause of death in the world. Previously, we designed pharmacologically optimized inhibitors against RHOA, including JK-136 and JK-139. Based on this previous work, we performed lead optimization and designed novel RHOA inhibitors for greater anti-GC potency. Two of these compounds, JK-206 and JK-312, could successfully inhibit the viability and migration of GC cell lines. Furthermore, using transcriptomic analysis of GC cells treated with JK-206, we revealed that the inhibition of RHOA might be associated with the inhibition of the mitogenic pathway. Therefore, JK-206 treatment for RHOA inhibition may be a new therapeutic strategy for regulating GC proliferation and migration.Keywords
Funding Information
- Gil Medical Center, Gachon University (FRD2019-11-02 (2))
- National Research Foundation of Korea (NRF-2020R1F1A1069206, NRF-2020R1I1A1A0106589212)
This publication has 61 references indexed in Scilit:
- Rational Design of Small Molecule Inhibitors Targeting RhoA Subfamily Rho GTPasesChemistry & Biology, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapyOncogene, 2011
- Small Molecule Probes of Cellular Pathways and NetworksACS Chemical Biology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeletonOncogene, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- CHARMM: The biomolecular simulation programJournal of Computational Chemistry, 2009
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002